Related Experiment Video
Updated: May 21, 2026
10:21
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
Effects of PPARγ Ligands on Leukemia
Yoko Tabe1, Marina Konopleva, Michael Andreeff
1Department of Clinical Laboratory Medicine, Juntendo University School of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan.
PPAR Research
|June 12, 2012
Summary
Peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RARs) show promise in treating hematological malignancies. Novel PPARγ ligands, including triterpenoids, are being explored for their antitumor effects in combination with RARα ligands.
Area of Science:
- Molecular Biology
- Oncology
- Cellular Biology
Background:
- Nuclear receptors, including Peroxisome proliferator-activated receptors (PPARs) and Retinoic Acid Receptors (RARs), regulate critical cellular functions.
- PPARs heterodimerize with the Retinoid X Receptor (RXR), a crucial partner for various nuclear receptors.
- Emerging evidence links retinoid metabolism to PPAR responses, with PPAR/RXR activation enhancing retinoid responsiveness.
Purpose of the Study:
- To review the antitumor advances of PPARγ, both as a monotherapy and in combination with RARα ligands.
- To explore the potential therapeutic applications of PPARγ and RARα ligands in hematological malignancies.
- To discuss the role of PPARγ in controlling cell proliferation, differentiation, and apoptosis.
Main Methods:
- Review of preclinical and clinical studies on PPARγ and RARα ligands in cancer.
- Analysis of the molecular mechanisms underlying the antitumor effects of these ligands.
- Evaluation of novel PPARγ ligands, such as triterpenoids, for therapeutic potential.
Main Results:
- PPARγ is a key regulator of cell growth and survival, modulated by various synthetic and natural ligands.
- Novel PPARγ ligands, distinct from thiazolidinediones (TZDs), are progressing in clinical trials for malignancies.
- Combinatorial therapy with PPARγ and RARα ligands shows potential in controlling cancer cell proliferation, differentiation, and apoptosis.
Conclusions:
- PPARγ and RARα ligands represent a promising therapeutic strategy for hematological malignancies.
- Further investigation into novel PPARγ ligands and their combination therapies is warranted for cancer treatment.
- Understanding the interplay between retinoid metabolism and PPAR signaling can lead to improved cancer therapies.
Related Concept Videos
01:09GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:31Transducer Mechanism: Nuclear Receptors
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:22Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...